Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visilizumab in Moderate-to-Severe Crohn's Disease
NCT00267722Phase 2Completed
- Sponsor
- Facet Biotech Corporation
- Start
- Feb 2005
- Primary completion
- Dec 2006
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of visilizumab in Crohn's disease, sponsored by Facet Biotech Corporation. Started Feb 2005; status: completed.
02
Drugs
visilizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00267722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267722.